Federica Giammarino

About me
Publications
Grants
Public outreach and news

About me

Federica received her Ph.D. in 2023 at the Department of Medical Biotechnology, University of Siena, Italy, on the in vitro characterization of novel antivirals for the treatment of multidrug resistant HIV-1, flaviviruses and coronaviruses. She joined us as postdoctoral researcher in October 2023. Her research focuses on the in vitro and ex vivo evaluation of compounds for the regulation of HIV latency/replication and on the role of biomaterials in combination with antiviral compounds as treatment and prophylaxis against sexually transmitted infections.

Articles

Journal article: ANTIVIRAL RESEARCH. 2025;239:106157
Combined doravirine and islatravir cooperate to inhibit NRTI and NNRTI resistant HIV-1 in vitro
Giammarino F; Paletti C; Bartolini N; Fiaschi L; Biba C; Varasi I; Foca E; Gulminetti R; Ferrara M; Comi L; Vicenti I; Castagna A; Zazzi M; Saladini F
Journal article: EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. 2024;277:116737
Optimization of potent, broad-spectrum, and specific anti-influenza compounds targeting RNA polymerase PA-PB1 heterodimerization.
Bonomini A; Felicetti T; Pacetti M; Bertagnin C; Coletti A; Giammarino F; De Angelis M; Poggialini F; Macchiarulo A; Sabatini S; Mercorelli B; Nencioni L; Vicenti I; Dreassi E; Cecchetti V; Tabarrini O; Loregian A; Massari S
Journal article: JOURNAL OF MEDICAL VIROLOGY. 2024;96(8):e29832
Regaining virological suppression in a woman living with a six-class resistant HIV by combining injectable antiretroviral drugs guided by genotypic and phenotypic tests
Monti B; Soria A; Saladini F; Lapadula G; Squillace N; Giammarino F; Paletti C; Bartolini N; Spagnuolo V; Castagna A; Zazzi M; Bonfanti P
Article: JOURNAL OF INFECTIOUS DISEASES. 2024;229(6):1796-1802
Prevalence and Phenotypic Susceptibility to Doravirine of the HIV-1 Reverse Transcriptase V106I Polymorphism in B and Non-B Subtypes.
Giammarino F; de Salazar A; Malet I; Viñuela L; Fuentes A; Saladini F; Bartolini N; Charpentier C; Lambert-Niclot S; Sterrantino G; Colao MG; Micheli V; Bertoli A; Fabeni L; Teyssou E; Delgado R; Falces-Romero I; Aguilera A; Gomes P; Paraskevis D; Santoro MM; Ceccherini-Silberstein F; Marcelin A-G; Moreno C; Zazzi M; García F
Article: NEW MICROBIOLOGICA. 2024
PRESTIGIO RING "a 59-year-old man with multidrug resistant HIV-1 infection failing a regimen including dolutegravir, rilpivirine, atazanavir/cobicistat: successful treatment tailoring based on genotypic and phenotypic resistance tests"
Panza F; Saladini F; Bartolini N; Giammarino F; Montagnani F; Spagnuolo V; Tumbarello M; Santoro MM; Castagna A; Zazzi M; Fabbiani M
Article: MOLECULES. 2024;29(7):1452
Serendipitous Identification of Azine Anticancer Agents Using a Privileged Scaffold Morphing Strategy
Cesarini S; Vicenti I; Poggialini F; Filippi S; Mancin E; Fiaschi L; De Marchi E; Giammarino F; Vagaggini C; Bizzarri BM; Saladino R; Dreassi E; Zazzi M; Botta L
Article: ORGANIC & BIOMOLECULAR CHEMISTRY. 2024;22(4):767-783
Switching the three-component Biginelli-like reaction conditions for the regioselective synthesis of new 2-amino[1,2,4]triazolo[1,5-a]pyrimidines
Pacetti M; Pismataro MC; Felicetti T; Giammarino F; Bonomini A; Tiecco M; Bertagnin C; Barreca ML; Germani R; Cecchetti V; Vicenti I; Tabarrini O; Zazzi M; Loregian A; Massari S
Article: VIRUSES-BASEL. 2024;16(2):168
In Vitro Combinatorial Activity of Direct Acting Antivirals and Monoclonal Antibodies against the Ancestral B.1 and BQ.1.1 SARS-CoV-2 Viral Variants.
Fiaschi L; Biba C; Varasi I; Bartolini N; Paletti C; Giammarino F; Saladini F; Zazzi M; Vicenti I
Article: FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY. 2024;14:1334126
Broad synergistic antiviral efficacy between a novel elite controller-derived dipeptide and antiretrovirals against drug-resistant HIV-1
Giammarino F; Sonnerborg A; Cena-Diez R
Article: CHEMMEDCHEM. 2023;18(16):e202300200
Nucleoside Derivatives of 2,6-Diaminopurine Antivirals: Base-Modified Nucleosides with Broad-Spectrum Antimicrobial Properties.
Grazia Martina M; Giammarino F; Vicenti I; Groaz E; Rozenski J; Incerti M; Sannio F; Docquier JD; Zazzi M; Radi M
Article: PHARMACEUTICALS. 2023;16(8):1118
HIV-1 Integrase Inhibition Activity by Spiroketals Derived from Plagius flosculosus, an Endemic Plant of Sardinia (Italy) and Corsica (France).
Sanna C; D'Abrosca B; Fiorentino A; Giammarino F; Vicenti I; Corona A; Caredda A; Tramontano E; Esposito F
Article: INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS. 2023;61(3):106737
Residual phenotypic susceptibility to doravirine in multidrug-resistant HIV-1 from subjects enrolled in the PRESTIGIO Registry
Saladini F; Giammarino F; Maggiolo F; Ferrara M; Cenderello G; Celesia BM; Martellotta F; Spagnuolo V; Corbelli GM; Gianotti N; Santoro MM; Rusconi S; Zazzi M; Castagna A
Article: MOLECULES. 2022;27(24):8829
Privileged Scaffold Decoration for the Identification of the First Trisubstituted Triazine with Anti-SARS-CoV-2 Activity
Cesarini S; Vicenti I; Poggialini F; Secchi M; Giammarino F; Varasi I; Lodola C; Zazzi M; Dreassi E; Maga G; Botta L; Saladino R
Article: JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2022;91(4):381-389
Dynamics of Total and Intact HIV-1 DNA in Virologically Suppressed Patients Switching to DTG-Based or ATV-Based Dual Therapy
Dragoni F; Rossetti B; Lombardi F; Raffaelli CS; Bartolini N; Giammarino F; Moschese D; Di Giambenedetto S; Fabbiani M; De Luca A; Vicenti I; Zazzi M; Saladini F
Article: VACCINES. 2022;10(8):1237
Long-Term Longitudinal Analysis of Neutralizing Antibody Response to Three Vaccine Doses in a Real-Life Setting of Previously SARS-CoV-2 Infected Healthcare Workers: A Model for Predicting Response to Further Vaccine Doses
Parisi SG; Mengoli C; Basso M; Vicenti I; Gatti F; Scaggiante R; Fiaschi L; Giammarino F; Iannetta M; Malagnino V; Zago D; Dragoni F; Zazzi M
Article: VIRUSES-BASEL. 2022;14(7):1374
Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2
Fiaschi L; Dragoni F; Schiaroli E; Bergna A; Rossetti B; Giammarino F; Biba C; Gidari A; Lai A; Nencioni C; Francisci D; Zazzi M; Vicenti I
Article: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2021;22(5):2670
Sofosbuvir Selects for Drug-Resistant Amino Acid Variants in the Zika Virus RNA-Dependent RNA-Polymerase Complex In Vitro
Boccuto A; Dragoni F; Picarazzi F; Lai A; Della Ventura C; Veo C; Giammarino F; Saladini F; Zehender G; Zazzi M; Mori M; Vicenti I
Article: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2021;76(1):130-134
In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations
Saladini F; Giammarino F; Hosseini BA; Giannini A; Boccuto A; Dragoni F; Vicenti I; Shafer RW; Zazzi M
Article: SLAS DISCOVERY. 2020;25(5):506-514
Development of a Cell-Based Immunodetection Assay for Simultaneous Screening of Antiviral Compounds Inhibiting Zika and Dengue Virus Replication
Vicenti I; Dragoni F; Giannini A; Giammarino F; Spinicci M; Saladini F; Boccuto A; Zazzi M
Article: ANTIVIRAL RESEARCH. 2020;175:104708
Evaluation of sofosbuvir activity and resistance profile against West Nile virus in vitro
Dragoni F; Boccuto A; Picarazzi F; Giannini A; Giammarino F; Saladini F; Mori M; Mastrangelo E; Zazzi M; Vicenti I

All other publications

Preprint: BIORXIV. 2025
Single-Shot Design of a Cyclic Peptide Inhibitor of HIV-1 Membrane Fusion with EvoBind
Daumiller D; Giammarino F; Li Q; Sönnerborg A; Diez RC; Bryant P
Conference publication: 2024;:a96.1-a9a96
SC-27 Comparative analysis of islatravir and tenofovir in vitro activity in NRTI resistant HIV-1 harboring the M184V/I mutation
Bartolini N; Paletti C; Giammarino F; Saladini F; Vicenti I; Fiaschi L; Biba C; Varasi I; Fabbiani M; Riccardi R; Lolatto R; Spagnuolo V; Castagna A; Zazzi M
Conference publication: 2024;:a273-a274
P-216 Evaluation of broad-spectrum piperazine-based compounds able to inhibit flavivirus and/or SARS-CoV-2 replication in a live virus assay
Biba C; Varasi I; Cavallaro P; Giammarino F; Bartolini N; Vega-Pérez J; Iglesias-Guerra F; Leggio A; Vega-Holm M; Vicenti I
Conference publication: 2024;:a20.1-a2a20
OC-19 The in vitro genetic barrier to resistance of lenacapavir is not affected by viral subtype or heavy treatment exposure
Paletti C; Bartolini N; Giammarino F; Saladini F; Vicenti I; Fiaschi L; Biba C; Varasi I; Garcia F; Marcelin A; Zazzi M; Spagnuolo V; Focà E; Rusconi S
Preprint: PREPRINTS.ORG. 2024
Serendipitous Identification of Azine Anticancer Agents by a Privileged Scaffold Morphing Strategy
Cesarini S; Vicenti I; Poggialini F; Filippi S; Mancin E; Fiaschi L; De Marchi E; Giammarino F; Vagaggini C; Bizzarri BM; Saladino R; Dreassi E; Zazzi M; Botta L
Preprint: PREPRINTS.ORG. 2024
In Vitro Combinatorial Activity of Direct Acting Antivirals and Monoclonal Antibodies against the Ancestral B.1 and BQ.1.1 SARS-CoV-2 Viral Variants
Fiaschi L; Biba C; Varasi I; Bartolini N; Paletti C; Giammarino F; Saladini F; Zazzi M; Vicenti I
Preprint: PREPRINTS.ORG. 2022
Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sub-Lineages BA.1 and BA.2
Fiaschi L; Dragoni F; Schiaroli E; Bergna A; Rossetti B; Giammarino F; Biba C; Gidari A; Lai A; Nencioni C; Francisci D; Zazzi M; Vicenti I
Letter: JOURNAL OF INFECTION. 2022;84(1):94-118
Decreased neutralization of the Eta SARS-CoV-2 variant by sera of previously infected and uninfected vaccinated individuals
Boccuto A; Dragoni F; Bergna A; Della Ventura C; Giammarino F; Saladini F; Pezzati L; Zehender G; Zazzi M; Vicenti I; Lai A
Letter: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2021;76(12):3310-3312
In vitro susceptibility of HIV-1 CRF02_AG to temsavir, the active compound of the attachment inhibitor fostemsavir
Saladini F; Giannini A; Giammarino F; Boccuto A; Dragoni F; Vicenti I; Zazzi M
Published conference paper: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2020;75(9):2547-2553
In vitro susceptibility to fostemsavir is not affected by long-term exposure to antiviral therapy in MDR HIV-1-infected patients
Saladini F; Giannini A; Giammarino F; Maggiolo F; Vichi F; Corbelli GM; Galli A; Bigoloni A; Poli A; Santoro MM; Zazzi M; Castagna A

Grants

Kartläggning av HIV-reservoarer för ART-avbrott och botstudier vid kronisk HIV-infektion: CHART-C-studien
Swedish Research Council
1 January 2025 - 31 December 2026
Development of intact provirus DNA assay for measurement of latent HIV DNA
Karolinska Institutet
1 January 2024 - 30 April 2025
Development of intact proviral DNA assay to measure latent HIV DNA in different HIV-1 subtypes.
Karolinska Institutet
1 January 2024 - 31 December 2025
Amount of HIV-1 DNA in the latent viral reservoir in people living with different HIV-1 subtypes
Stiftelsen Läkare Mot AIDS Forskningsfond

About me

Articles

All other publications

Grants

News from KI

Events from KI